Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine.

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth by more than eight months, according to a study that may expand its use.

Pfizer Inc. reached a deal with the Securities and Exchange Commission in which the drugmaker would collect $29 million to ...

Bloomberg reports that in what seems to be a page from Glaxo's Avandia playbook, Pfizer has begun wholesale settlements with plaintiffs lawyers who control dockets of Prempro cases. • ALSO ...

(Bloomberg) -- A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders. The death occurred on Dec. 14 after the ...

(Bloomberg) -- A next-generation treatment for breast cancer from Pfizer Inc. and Arvinas Inc. posted disappointing results in a final-stage study, a potential setback for a drug Pfizer once called a ...

Pfizer (NYSE:PFE) reported lower fourth-quarter revenue as demand for its COVID-19 treatments continued to fade, but stronger ...

Pfizer beat fourth-quarter sales estimates on strength from its older drugs as it races to fill gaps from its declining covid shot and pill franchises. Pfizer battled to acquire obesity startup ...